Monte Rosa Therapeutics (NASDAQ: GLUE) holders cut stake to 4.99%

Rhea-AI Filing Summary

Versant-affiliated funds reported a lower ownership stake in Monte Rosa Therapeutics, Inc. In Amendment No. 6 to their Schedule 13D, the reporting persons disclose aggregate beneficial ownership of 3,250,069 shares of Common Stock, representing 4.99% of the company’s outstanding shares, based on 65,117,761 shares outstanding as of October 31, 2025. The holdings consist of 2,236,708 shares held by Versant Venture Capital VI, L.P. and 1,013,361 shares held by Versant Vantage I, L.P.

The filing details recent activity, including several open-market sales and pro rata distributions to limited partners. Versant VI sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026. Versant VI also distributed 500,030 shares to its limited partners on December 4, 2025, and Versant Vantage I distributed 560,092 shares on January 8, 2026, both on a pro rata basis without additional consideration.

Insights

Equity ownership & filings analyst

Versant funds reduced and redistributed part of their Monte Rosa stake, now at 4.99%.

The filing shows that Versant-affiliated entities now beneficially own 3,250,069 Monte Rosa Therapeutics shares, equal to 4.99% of the 65,117,761 shares outstanding as of October 31, 2025. This is spread between Versant Venture Capital VI, L.P. with 2,236,708 shares and Versant Vantage I, L.P. with 1,013,361 shares, with various general partner entities sharing voting and investment power as described.

Recent activity includes several sales by Versant VI and pro rata distributions to limited partners. Versant VI sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026, for aggregate proceeds of about $13.75M as stated in the individual lines. In addition, Versant VI distributed 500,030 shares on December 4, 2025 and Versant Vantage I distributed 560,092 shares on January 8, 2026 to their limited partners without additional consideration.

This sequence of sales and distributions results in the group’s ownership moving just under the 5% threshold, which is reflected in the 4.99% figure in the amendment. The document does not state any change in strategy or relationship with the issuer, so the main takeaway is an updated ownership level and a record of recent share movements by these investment funds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Monte Rosa Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

61225M102

(CUSIP Number)

Max Eisenberg
One Sansome Street, Suite 1650,
San Francisco, CA, 94104
415-801-8100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/07/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Venture Capital VI, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,236,708.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,236,708.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,236,708.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares are held by Versant VI (as defined in Item 2(a) of the Original Schedule 13D). Versant Ventures VI GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Ventures VI GP (as defined in Item 2(a) of the Original Schedule 13D), which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of October 31, 2025, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on November 6, 2025 (the "Form 10-Q").

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Ventures VI GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,236,708.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,236,708.00

11

Aggregate amount beneficially owned by each reporting person

2,236,708.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Ventures VI GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,236,708.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,236,708.00

11

Aggregate amount beneficially owned by each reporting person

2,236,708.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

All shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Vantage I, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,013,361.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,013,361.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,013,361.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares are held by Versant Vantage I (as defined in item 2(a) of the Original Schedule 13D). Versant Vantage I GP (as defined in item 2(a) of the Original Schedule 13D) is the general partner of Versant Vantage I, and Versant Vantage I GP-GP (as defined in item 2(a) of the Original Schedule 13D) is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP and Versant Vantage I GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage I. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Vantage I GP, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,013,361.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,013,361.00

11

Aggregate amount beneficially owned by each reporting person

1,013,361.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All shares are held by Versant Vantage I. Versant Vantage I GP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP and Versant Vantage I GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage I. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13D

CUSIP No. 61225M102

1

Name of reporting person

Versant Vantage I GP-GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,013,361.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,013,361.00

11

Aggregate amount beneficially owned by each reporting person

1,013,361.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.6 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

All shares are held by Versant Vantage I. Versant Vantage I GP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP. Each of Versant Vantage I GP and Versant Vantage I GP-GP share voting, investment and dispositive power over the shares held by Versant Vantage I. The percentage in Row 13 is based on 65,117,761 shares of the Issuer's Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Monte Rosa Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 321 Harrison Avenue, Suite 900, Boston, MASSACHUSETTS , 02118.
Item 1 Comment: This Amendment No. 6 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on July 8, 2021, as amended by Amendment No. 1 filed with the Commission on November 9, 2023, Amendment No. 2 filed with the Commission on August 12, 2024, Amendment No. 3 filed with the Commission on September 24, 2024, Amendment No. 4 filed with the Commission on October 30, 2024, and Amendment No. 5 filed with the Commission on November 12, 2025 (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. The information reported in this Amendment is based on the Reporting Persons' holdings as of January 8, 2026. The aggregate percentage ownership of the Reporting Persons is 4.99%, calculated by taking 3,250,069 aggregate shares of Common Stock held by the Reporting Persons, which consists of (i) 2,236,708 shares of Common Stock held by Versant VI plus (ii) 1,013,361 shares of Common Stock held by Versant Vantage I and dividing it by 65,117,761 shares of Common Stock outstanding as of October 31, 2025, as reported by the Issuer in the Form 10-Q.
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(b)	See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
(c)	On November 19, 2025, Versant VI sold 15,200 shares of Common Stock at a weighted average price per share of $14.2503 for aggregate proceeds of approximately $216,605.02. On December 4, 2025, Versant VI effected a pro rata distribution without additional consideration of 500,030 shares of Common Stock to its limited partners. On December 16, 2025, Versant VI sold 10,205 shares of Common Stock at a price per share of $17.64 for aggregate proceeds of approximately $180,016.20. On January 7, 2026, Versant VI sold 572,526 shares of Common Stock at a weighted average price per share of $23.3304 for aggregate proceeds of approximately $13,357,260.59. On January 8, 2026, Versant Vantage I effected a pro rata distribution without additional consideration of 560,092 shares of Common Stock to its limited partners.
(e)	January 8, 2026

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Versant Venture Capital VI, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Date:	01/09/2026

Versant Ventures VI GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the General Partner of Versant Ventures VI GP, L.P.
Date:	01/09/2026

Versant Ventures VI GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO
Date:	01/09/2026

Versant Vantage I, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P.
Date:	01/09/2026

Versant Vantage I GP, L.P.

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the General Partner of Versant Vantage I GP, L.P.
Date:	01/09/2026

Versant Vantage I GP-GP, LLC

Signature:	/s/Max Eisenberg
Name/Title:	Max Eisenberg/COO
Date:	01/09/2026

FAQ

What ownership stake in Monte Rosa Therapeutics (GLUE) do the Versant funds now report?

The reporting persons state they beneficially own an aggregate of 3,250,069 shares of Monte Rosa Therapeutics Common Stock, representing 4.99% of the 65,117,761 shares outstanding as of October 31, 2025, based on the issuer’s Form 10-Q.

How are the reported Monte Rosa Therapeutics (GLUE) shares split between Versant VI and Versant Vantage I?

The filing explains that Versant Venture Capital VI, L.P. holds 2,236,708 shares of Common Stock, while Versant Vantage I, L.P. holds 1,013,361 shares. Together these positions total 3,250,069 shares, or 4.99% of the issuer’s outstanding Common Stock.

What recent share sales by Versant VI in Monte Rosa Therapeutics (GLUE) are disclosed?

Versant VI is reported to have sold 15,200 shares at a weighted average price of $14.2503 on November 19, 2025, 10,205 shares at $17.64 on December 16, 2025, and 572,526 shares at a weighted average price of $23.3304 on January 7, 2026. The filing provides aggregate proceeds for each of these transactions.

What pro rata distributions of Monte Rosa Therapeutics (GLUE) shares are described in the amendment?

The document states that on December 4, 2025, Versant VI made a pro rata distribution of 500,030 Common Stock shares to its limited partners without additional consideration. On January 8, 2026, Versant Vantage I similarly distributed 560,092 Common Stock shares to its limited partners without additional consideration.

Which entities share voting and investment power over the Monte Rosa Therapeutics (GLUE) shares held by the Versant funds?

For Versant VI, the filing notes that Versant Ventures VI GP, L.P. is its general partner and Versant Ventures VI GP-GP, LLC is the general partner of Versant Ventures VI GP, and these entities may be deemed to share voting, investment and dispositive power over the 2,236,708 shares held by Versant VI. For Versant Vantage I, Versant Vantage I GP, L.P. and Versant Vantage I GP-GP, LLC are described in similar roles for the 1,013,361 shares held by Versant Vantage I.

What is the effective date of the ownership information in this Monte Rosa Therapeutics (GLUE) Schedule 13D amendment?

The amendment states that the information reported is based on the reporting persons’ holdings as of January 8, 2026, with the percentage calculated using the issuer’s outstanding share count as of October 31, 2025.